[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354847-105":59,"doc-detail-354847-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","genomic-profile-and-resistance-to-anti-epidermal-growth-factor-receptor-antibody-in-ras-amplified-colorectal-cancer-a-study-based-on-a-japanese-cancer-genome-database","Genomic Profile and Resistance to Anti-Epidermal Growth Factor Receptor Antibody in RAS-Amplified Colorectal Cancer - A Study Based on a Japanese Cancer Genome Database","","Study characterizes RAS-amplified colorectal cancer and evaluates tumor sensitivity to anti-EGFR antibodies. A retrospective observational analysis used Japan’s Center for Cancer Genomics and Advanced Therapeutics database and FoundationOne CDx data from 9,135 patients with unresectable colorectal adenocarcinoma. RAS amplification appeared in 2.1% of cases and associated with lower ORR and shorter TTF versus RAS wild type on anti-EGFR therapy, while bevacizumab showed no significant differences. Findings suggest RAS amplification may confer anti-EGFR resistance.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomic-profile-and-resistance-to-anti-epidermal-growth-factor-receptor-antibody-in-ras-amplified-colorectal-cancer-a-study-based-on-a-japanese-cancer-genome-database/354847/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomic-profile-and-resistance-to-anti-epidermal-growth-factor-receptor-antibody-in-ras-amplified-colorectal-cancer-a-study-based-on-a-japanese-cancer-genome-database/354847.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of this study on RAS amplification in colorectal cancer?","Question",{"text":112,"@type":113},"The study aimed to characterize RAS-amplified colorectal cancer and evaluate sensitivity to anti-EGFR antibodies, since the clinical impact of RAS amplification on anti-EGFR efficacy was unclear.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study conducted and what patient data were used?",{"text":117,"@type":113},"A retrospective observational study used Japan’s Center for Cancer Genomics and Advanced Therapeutics database and analyzed genomic and clinical data from 9,135 patients with unresectable colorectal adenocarcinoma who underwent FoundationOne CDx testing.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about RAS amplification with first-line anti-EGFR therapy?",{"text":121,"@type":113},"Among RAS wild-type patients treated with first-line anti-EGFR antibodies, RAS amplification was linked to a lower overall response rate and a shorter time to treatment failure compared with those without RAS amplification.",{"name":123,"@type":110,"acceptedAnswer":124},"Did RAS amplification affect outcomes for patients treated with bevacizumab?",{"text":125,"@type":113},"No. In the bevacizumab-treated group, there were no significant differences in overall response rate or time to treatment failure between patients with and without RAS amplification.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},354847,1790193664,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Original Reports | Biomarkers  \nGenomic Proﬁle and Resistance to Anti-Epidermal Growth Factor Receptor Antibody in RAS-Ampliﬁed Colorectal Cancer: A Study Based on a Japanese Cancer  \nGenome Database  \nGota Fujisawa, MD, PhD1 ; Kenji Tamada, MD1; Takeshi Hayashi, MD1; Nobumi Suzuki, MD, PhD1  ; Takuma Iwata, MD, PhD1 ;  \nYu Miyakawa, MD, PhD1 ; Masahiro Hata, MD, PhD1; Rei Ishibashi, MD, PhD1 ; Yoku Hayakawa, MD, PhD1; Aya Shinozaki-Ushiku, MD, PhD2; Hidenori Kage, MD, PhD2  ; Katsutoshi Oda, MD, PhD2; Narikazu Boku, MD, PhD1,3  ; and Mitsuhiro Fujishiro, MD, PhD1   \nDOI [https://doi.org/10.1200/PO-25-00424](https://doi.org/10.1200/PO-25-00424)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | RAS mutation is a key biomarker of anti–epidermal growth factor receptor (EGFR) antibody resistance in colorectal cancer (CRC) . However, the clinical impact of RAS ampliﬁcation on the efﬁcacy of anti-EGFR therapy remains unclear. This study aimed to characterize RAS-ampliﬁed CRC and evaluate the sensitivity of these tumors to anti-EGFR antibodies. |\n| METHODS | We conducted a retrospective observational study using the Center for Cancer Genomics and Advanced Therapeutics database in Japan, which includes clinical and genomic data from patients who underwent comprehensive genomic proﬁling. We analyzed the data from 9,135 patients with unresectable colorectal adenocarcinoma (CRA) who underwent FoundationOne CDx testing. |\n| RESULTS | RAS ampliﬁcation was identiﬁed in 2.1%(188/9,135) of patients with CRA. Among 1,649 patients with RAS wild-type CRA who received ﬁrst-line chemotherapy with anti-EGFR antibodies, those with RAS ampliﬁcation had a lower overall response rate (ORR) and a shorter time to treatment failure (TTF) compared with those without RAS ampliﬁcation (ORR, 37.5%[21/56] v 52.9%[843/1,593]; median TTF, 195 days [95% CI, 129 to 224] v 274 days [95% CI, 258 to 293]; P 5 .023 and P 5 .005, respectively). By contrast, among 4,858 patients treated with bevacizumab, no signiﬁcant differences were observed in ORR (37.3%[31/83] v 37.1%[1,772/4,775]; P 5 .964) or TTF (median, 231 days [95% CI, 175 to 273] v 259 days [95% CI, 252 to 270]; P 5 .445) . |\n| CONCLUSION | RAS ampliﬁcation is a rare alteration that may confer resistance to anti-EGFR antibodies. Assessing RAS ampliﬁcation status may help guide the appropriate use of anti-EGFR antibodies in clinical practice. |\n\nACCOMPANYING CONTENT  \n Data Sharing Statement  \n Data Supplement  \nAccepted October 21, 2025 Published January 8, 2026  \nJCO Precis Oncol 10:e2500424 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nColorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide, making it a signiﬁcant disease globally.1  \nAlthough key drugs for unresectable CRC include anti– epidermal growth factor receptor (EGFR) antibodies, such as cetuximab and panitumumab, their beneﬁts are limited to a subset of patients. Guidelines from the European Society for Medical Oncology, National Comprehensive Cancer Network, and Japanese Society for Cancer of the Colon and Rectum recommend anti-EGFR antibodies as ﬁrst-line chemotherapy only for patients with RAS/BRAF wild-type, left-sided primary tumors.2-4 In addition,  \nrecent studies have suggested that integrating multiple other genetic alterations can more accurately predict resistance to anti-EGFR antibodies.5 , 6  \nRAS mutation is the most well-established biomarker for resistance to anti-EGFR antibodies. The RAS protein has three isoforms: KRAS, NRAS, and HRAS, which are activated by stimuli from receptors such as EGFR, triggering downstream signaling that drives normal cellular proliferation.7 Because RAS mutations cause the RAS protein to be constitutively active without EGFR stimulation, they drive oncogenesis and cancer progression, and confer resistance to anti-EGFR antibodies in CRC.8,9 KRAS mutations","cbCaicIAJRiQRtgJ","https://ap.wps.com/l/cbCaicIAJRiQRtgJ","pdf",2123625,14,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Context","[{\"question\":\"What was the purpose of this study on RAS amplification in colorectal cancer?\",\"answer\":\"The study aimed to characterize RAS-amplified colorectal cancer and evaluate sensitivity to anti-EGFR antibodies, since the clinical impact of RAS amplification on anti-EGFR efficacy was unclear.\"},{\"question\":\"How was the study conducted and what patient data were used?\",\"answer\":\"A retrospective observational study used Japan’s Center for Cancer Genomics and Advanced Therapeutics database and analyzed genomic and clinical data from 9,135 patients with unresectable colorectal adenocarcinoma who underwent FoundationOne CDx testing.\"},{\"question\":\"What did the results show about RAS amplification with first-line anti-EGFR therapy?\",\"answer\":\"Among RAS wild-type patients treated with first-line anti-EGFR antibodies, RAS amplification was linked to a lower overall response rate and a shorter time to treatment failure compared with those without RAS amplification.\"},{\"question\":\"Did RAS amplification affect outcomes for patients treated with bevacizumab?\",\"answer\":\"No. In the bevacizumab-treated group, there were no significant differences in overall response rate or time to treatment failure between patients with and without RAS amplification.\"}]","Genomic Profile and Resistance to Anti-Epidermal Growth Factor Receptor Antibody in RAS-Amplified Colorectal Cancer - A Study Based on a Japanese Cancer Genome Database | PDF",1790114404,35,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ccd461213ad0bd0a6e47c8ac1b2e7f48.webp",983,1315,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c4d4eb775b4242f2b00299b04b90cf6.webp",982,1314,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab66953d667fe0292a88fd5b9f71501d.webp",981,1312,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a55199d2ac1a1bc6c871fd855f0f749d.webp",980,1311]